News Release

Patent `Method of purifying Tetrodotoxin` issued by USPTO

Date: May 26 , 2003

TSX Venture Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

This patent covers the manufacturing technologies for extracting tetrodotoxin (TTX) from biological tissues. Along with another US patent under the title of "System for Extracting Tetrodotoxin" issued to the Company earlier, it enables the production of TTX with high yield and at a commercially viable scale. Aimed at serving millions of patients throughout the world, the manufacturing technologies for TTX, as the platform substance of the Company's drug products, have been made ready and protected. The Company will continue to build its intellectual properties, including patents and registered trademarks, and obtain protection world wide.

This patent covers the manufacturing technologies to purify the crude extract so as to obtain pharmaceutical-grade tetrodotoxin (TTX) substance. In addition, with two other US patents issued to the Company earlier, this completes the protection for the entire manufacturing technologies of TTX with clinically required high purity and at a commercially viable scale. The Company will continue to build its intellectual properties, including patents and registered trademarks, and obtain protection world wide.

In the area of neuro-bioscience, the Company is focusing on the fields of pain management, drug addiction treatment and anaesthesia. The Company is developing products that contain a sodium channel blocking compound and derivatives extracted from natural organic substances using its proprietary manufacturing technology.

For additional information on our products, view the Company website at http://www.wextech.ca or call Gordon Stanley at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.